The subscription period in Dignitana's rights issue starts today

Files for download
Dignitana Release - wkr0006.pdf



Today, on 18 March 2024, the subscription period begins in Dignitana AB (publ)'s ("Dignitana" or the "Company") rights issue of shares, which was announced on 21 February 2024 (the "Rights Issue"). The subscription period runs up to and including 2 April 2024. However, please note that nominees may have a last response date for subscription in the Rights Issue that occurs before 2 April 2024. Upon full subscription in the Rights Issue, the Company will receive approximately MSEK 19.1 before issue costs. The proceeds from the Rights Issue are primarily intended to be used to finance the Company’s ongoing expansion, increase sales and marketing initiatives, increase reimbursement program support, introduce service in the field in the US, expand the product portfolio and repay loans.

Summary of the Rights Issue

  • All existing shareholders on the record date of 14 March 2024 received one (1) subscription right for each one (1) share held on the record date of 14 March 2024, and seven (7) subscription rights entitle the holder to subscribe for one (1) share.
  • The subscription price amounts to SEK 1.90 per share.
  • The Rights Issue entails an issue of a maximum of 10,067,736 shares and will, if fully subscribed, provide Dignitana with approximately MSEK 19.1, before issue costs.
  • The subscription period for the Rights Issue runs from today, 18 March 2024, up to and including 2 April 2024. Subscription rights that are not exercised during the subscription period become invalid and thus lose their value.
  • The Rights Issue is covered to approximately 35.7 percent by subscription undertakings, approximately 31.4 percent by bottom underwriting undertakings and approximately 26.1 percent by top underwriting undertakings. Thus, the Rights Issue is secured to approximately 93.2 percent. However, underwriting undertakings and subscription undertakings has not been secured by bank guarantees, pledges or similar arrangements.


No prospectus will be registered with the Swedish Financial Supervisory Authority (Sw: Finansinspektionen) and no information memorandum will be published in connection with the Rights Issue. Conditions and instructions, as well as certain additional information to investors, are available on the Company’s website


Timetable for the Rights Issue, all dates occur within 2024


18 March – 2 April

Subscription period in the Rights Issue

18 March – 26 March

Trading in subscription rights on Nasdaq First North Growth Market

18 March – registration of the Rights Issue with the Swedish Companies Registration Office

Trading in BTA on Nasdaq First North Growth Market

5 April

Estimated date for publication of the outcome of the Rights Issue



Fredersen Advokatbyrå AB is the legal advisor and Nordic Issuing AB is the issuing agent to Dignitana in connection with the Rights Issue.



Important Information

The publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. No action has been taken and no action will be taken to permit an offer to the public in jurisdictions other than Sweden.


Any investment decision in connection with the Rights Issue shall be made based on all publicly available information relating to the Company. The information in this press release is published only as background information and does not claim to be complete. Accordingly, an investor should not rely solely on the information in this press release or its accuracy or completeness.


This press release may not be announced, published, or distributed, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell shares, subscription rights, BTAs or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require other prospectus, registration or other measures other than under Swedish law. The application form and other documents related to the Rights Issue may not be distributed in or to any country where such distribution or the Rights Issue requires measures as stated in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws.


None of the shares, subscription rights, BTAs or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered or transferred, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.


As Dignitana has made the assessment that the Company conducts activities worthy of protection under The Foreign Direct Investment Screening Act (2023:560), certain investments in the Rights Issue may require review by the Swedish Inspectorate of Strategic Products. For more information, please visit the Swedish Inspectorate of Strategic Products’ website,, or contact the Company.


Forward-looking statements

This press release may contain some forward-looking statements that reflects the Company’s current view of future events and financial and operational development.  Words such as “intend”, “consider” “expect”, “may”, “plan”, “believe”, “estimate” and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By its nature, forward-looking statements involves known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking statements is not a guarantee of future results or development and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the Nasdaq First North regulations for issuers.



For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at or